CONNECT WITH US
Web3 & Blockchain

Web3 & Blockchain

Hims & Hers Health (HIMS) Stock Price Prediction: Oversold, but the Trend Is Still Fighting Gravity

Blockchain.News logo

Published on

Add as a preferred source on Google
Hims  &  Hers Health (HIMS) Stock Price Prediction: Oversold, but the Trend Is Still Fighting Gravity

Hims & Hers Health (HIMS) fell 4.32% to $17.73, leaving the stock below its 7-, 20- and 50-day moving averages. The latest readout shows oversold momentum and constructive buy-side activity on Bina...

HIMS shares closed at $17.73, down 4.32% on the session, with a 24-hour range of $18.70 to $17.16. That leaves the stock below its 7-day SMA of $18.89, its 20-day SMA of $22.82 and its 50-day SMA of $26.54, a clean bearish alignment that tells you the intermediate trend is still pointed lower.

At the same time, the stock is no longer acting stretched on the downside. The 14-day RSI sits at 28.03, which is in oversold territory, while %B at 0.1526 shows price sitting close to the lower Bollinger Band at $15.50. That does not guarantee a bounce, but it does mean the selloff is approaching levels where mean reversion becomes more plausible.

The key question is whether HIMS can stabilize above the pivot point at $17.86 and defend immediate support at $17.03. If it can, the first test is immediate resistance at $18.57, with stronger resistance at $19.40 beyond that.

If $17.03 fails, the chart opens toward strong support at $16.32. With ATR(14) at $1.92, the stock has enough daily volatility to move through these levels quickly, so traders should treat the nearby support band as a real battleground rather than a soft floor.

The moving-average structure is the main constraint here. A stock can be oversold and still stay weak if the broader trend remains under pressure, and HIMS is still trading well below all major short-term trend gauges.


Source link

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.